Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome

INTRODUCTION: The purpose of this study is to report our functional and anatomical results of intravitreal ranibizumab (IVR) for choroidal neovascularization secondary to pathological myopia (mCNV).
METHODS: In this retrospective study, 32 mCNV patients’ 32 eyes were evaluated. After one IVR injection patients were followed by an as-needed monthly regime. Best-corrected visual acuity (BCVA) and optic coherence tomography (OCT) findings were evaluated at baseline and then monthly. Re-injection criteria were; reduction in visual acuity and/or increase in central macular thickness measured with OCT.
RESULTS: The mean age of the subjects was 57.7±14.6 years, and the mean axial length was 27.8±1.3 mm. Mean visual acuity improved significantly from 46.4±9.7 letters at baseline to 54.1±9.5 letters at last follow-up visit (p<0.05). The mean central macular thickness decreased from 301.4±11.7 μm at baseline to 258.8 ±12.5 μm at the last visit (p>0.05). The average number of injections was 3.5±1,1, 2.3±0.9 and 1.7±0.8 injections at 12, 24 and 36 months respectively.
DISCUSSION AND CONCLUSION: This study has shown that IVR injections provide a significant long-term visual and anatomical benefit in mCNV with a small number of injections.